Rossari Q1 record revenue but margin miss, guidance flip on EO and EBITDA floor
Revenue jumped 28% to ₹697 cr, but EBITDA margin slipped to 11.6% from 12.5%, and management lowered the near-term margin floor without reconciling to prior guidance.
What's new
- Record revenue ₹697 cr, up 28% YoY, driven by volume growth of 10% and higher pricing.
- EBITDA margin fell to 11.6% from 12.5% due to freight, insurance, and EO constraints.
- HSPC crossed ₹550 cr, growing 28% YoY, supported by personal care and pharma applications.
- B2C exit expected to release 2-3% EBITDA margin; debt close to ₹50 cr.
Themes from the call
Demand
Volume grew 10%, pricing contributed 18%, with all core segments (HSPC, textiles, animal health) growing ~28% YoY.
Margins
Consolidated EBITDA margin compressed to 11.6% from 12.5%, with core B2B at 14% but diluted by institutional and consumer losses.
Capital allocation
Portfolio rationalization ongoing: B2C exit, institutional business retained; monetized underutilized office; no new broad capex planned.
Guidance watch
- FY27 top-line growth reaffirmed at 15% despite strong Q1.
- 11.6% EBITDA margin viewed as base; target of 14%+ in two years.
- Pharma FY27 revenue guidance conflicted: ₹30-50 cr vs ₹70-75 cr.
- EO availability expected before December; margin outcome dependent on pricing and mix.
Risk flags
- EBITDA margin floor lowered without reconciling prior 12-13% guidance.
- EO supply reversal from 'stable' to 'constrained' weakens supply visibility.
- Pharma revenue guidance conflict unresolved.
- B2C debt of ~₹50 cr could linger if exit delays.
- Saudi Arabia still exploratory, no finalized timeline.
Key quotes
-
"This year, I will still stick to 15.0% top-line growth. Even though this has been a strong quarter, global events make it difficult to predict on a quarterly basis."
— Sunil Chari, on Q&A -
"Currently, the EBITDA margins will remain at these current levels between 12% to 13%."
— Management, April 2026 call -
"Yes, we are expecting the same thing as well. I think these level of margins can be expected to be the base level."
— Management, July 2026 call
The brief
Rossari Biotech delivered a record quarterly revenue of ₹697 crore, up 28% year-on-year, driven by volume growth and pricing across its core segments. But the headline number masks a margin squeeze. Consolidated EBITDA margin fell to 11.6% from 12.5% a year ago, missing the 12-13% range management had guided for just three months ago. On the call, management accepted that 11.6% could be the base, effectively lowering the near-term floor without explaining the change. The contradiction is compounded by a flip on ethylene oxide supply. In April, management called EO supply stable. Now it is constrained, with new EO availability only expected by year-end. The change weakens the credibility of supply forecasts. The company's response to the margin pressure is a portfolio reset: exiting consumer-facing B2C businesses (worth ~2-3% margin improvement) while retaining institutional cleaning, and focusing on capacity utilization, product mix, and cost discipline. International expansion continues with a small Thailand plant and an exploratory Saudi project. But the revenue guidance of 15% for FY27 relies on pharma ramp-up, where guidance is itself conflicted between ₹30-50 crore and ₹70-75 crore. Rossari's revenue momentum is real. But the margin trajectory and the reliability of its guidance are now open questions.
Record revenue growth, but margin guidance whiplash raises questions about the base the company is building from.